chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information was received on 25-JUL-2017 from a lawyer regarding a case in litigation concerning a male patient of unknown age. The patient was inoculated with a dose of ZOSTAVAX vaccine on or about 03-OCT-2014, prescribed by a physician and administered at a medical facility, as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. One week later, on or about 11-NOV-2014, the patient was treated at the emergency room for severe headaches, floaters in the eye, and pain, which was diagnosed by a physician as herpes zoster eruptions causing headache and other interferences. On or about 20-NOV-2015, the patient was treated by his physician for ongoing and worsening symptoms of vesicular outbreaks, which were diagnosed as additional herpes zoster infections. On or about 15-APR-2015, the patient was treated by a physician at a medical facility for severe residual pain, which was diagnosed as post-herpetic neuralgia. The patient has been prescribed acyclovir (manufacturer unknown), nortriptyline (manufacturer unknown) and gabapentin (manufacturer unknown) for management of his painful symptoms. The subsequent medications required to treat the patient's recurrent shingles have resulted in memory loss and other cognitive issues that affect his daily life. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain and suffering, and other damages. Additional information has been requested.
Pfizer vaccine temperature excursion. The vaccine was in the freezer for 3 weeks, then it was removed to the fridge and administered to patients.
24hrs p/inj 2 lymph nodes in lt supraclavicular area; inj site lt deltoid indurated & red & tender was unable to sleep on same Wednesday noc; no fever was fine otherwise & went to school everyday
Weight loss/ lost 6lb in two days after the second dose; This spontaneous case was reported by a consumer and describes the occurrence of WEIGHT DECREASED (Weight loss/ lost 6lb in two days after the second dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WEIGHT DECREASED (Weight loss/ lost 6lb in two days after the second dose). At the time of the report, WEIGHT DECREASED (Weight loss/ lost 6lb in two days after the second dose) outcome was unknown.            No concomitant medications were reported by the reporter.  Treatment medication was not provided by the reporter.   Reporter did not allow further contact
All over body rash.  5 days after the first.  Continues through the second shot
Patient waited to present to the pharmacy untl 10/6/17 at 7:30 PM to report reaction. Patient received shot on 10/1/17 at 11:15 AM and reports starting to have a reaction that evening. Patient has excessive swelling and redness. Patient reported having a golf-ball size redness/swelling at injection site and presented with extreme redness to his elbow. Patient says it is getting better, but he just wanted to make sure other patients also have reported this reaction. He says he will use a cold compress on red area. He did not report it being painful. He does not have a PCP, but I.
On Thursday, 9/22 at 12:00 noon I received the Covid Moderna Bivalent Booster at the same time as receiving the Flu Shot but in different arms.  I had tiredness for 24 hours but was fine after that.  On Saturday, 9/24 at 4:00pm, I started to get tingling in my fingers/hand.   This continued and wasn't constant, re-occuring about every 30 minutes.  Around 1:00am on Sunday, 9/25, the tingling moved to my feet and spread up my calves and caused some slight numbness in the feet for a short period of time.  The tingling in the feet stopped around 2:00am on 9/25 but as of 11:00am on 9/25, I am still experiencing tingling in my hands/fingers.
This case was reported by a consumer and described the occurrence of swelling arm in a female patient who received HAVRIX. On an unknown date, the patient received HAVRIX (intramuscular). On an unknown date, an unknown time after receiving HAVRIX, the patient experienced swelling arm and pain in arm. On an unknown date, the outcome of the swelling arm and pain in arm were unknown. It was unknown if the reporter considered the swelling arm and pain in arm to be related to HAVRIX. Additional information: An adult female patient reports that her nurse may not have injected into her deltoid in her arm. She reports that the injection site looks like it is more forward on her arm, rather than towards the middle. The patient noted that the nurse who gave her the injection insists it was done correctly.
Vaccine was administered at approximately 8pm pt described having trouble swallowing for a moment and feeling slightly faint when walking out of the vaccination room. She says she tried to drink some water but felt as if her throat was closing up, pharmacist advised she take a benadryl. She described a sensation of being sweaty and as if her face was slightly swollen about 10 minutes post vaccination, whereupon patient agreed to take a benadryl 25mg. By 20 minutes post-vaccination patient stated that she was fine and wanted to leave with her friend. Pharmacist advised she follow up with clinic as needed for any recurring symptoms.
Mom recv vax,had baby;baby had thrombocytopenia & GI bleeding; Rx w/frequent platelet&packed RBC transfusions;bone marrow suppression suggested by persistent leukopenia;child intubated & mechanically ventilated;baby died on 30th day of life
Erythema under let arm noted 4 hours after injection in L deltoid. Additional erythema noted, 18 hours after injection, on L breast. Red, linear, slightly raised. No itching. Treated with one application of Bacitracin.
This spontaneous report was received from a physician via company representative refers to a female patient (nurse practitioner) who is currently 52 years old. The patient's pertinent medical history included asthma. Drug Reactions/Allergies were unknown. On an unknown date in October 2016, the patient was vaccinated with ZOSTAVAX lot # L027321, expiry date 21-OCT-2016, 0.65 ml, subcutaneous route for the prevention of shingles. Concomitant therapies included unspecified flu vaccine (unspecified) vaccinated a week prior to ZOSTAVAX. Approximately in October 2016 (reported as "on the first day after ZOSTAVAX vaccination), the patient developed a "swollen elongated wheal type rash and it was raised." Approximately in 2016 (reported as "on the second day of vaccination"), the patient's arm "had a softball size welt that was warm to the touch" and on the third day of post vaccination, the rash was improving, became lighter. However, the patient felt "super tired but couldn't sleep" and experienced severe muscle aches and severe rigors". Approximately in 2016 (reported as "on the 4th day of vaccination"), the patient developed a bad fever of 104 degrees, headache. The patient still had muscle aches, but the aches were more mild. The rash was still present although the rash continued to lessen and become lighter. The patient was treated with ADVIL and TYLENOL for the adverse events. On the fifth day of vaccination, the patient started to recover from her adverse reactions. At the time of reporting, the patient had full recovery from the adverse events (approximately in 2016). Causality assessment was not provided. Product quality complaint (PQC) was not involved. No further information was available. Additional information has been requested.
A non-serious spontaneous report of extreme vomiting has been received from a consumer concerning a 37-year-old male, subsequent to H1N1, Intranasal. Neither relevant medical history nor concomitant medications have been reported for this patient. On 02-Dec-2009, the patient received H1N1, Intranasal, for an unknown indication. On 03-Dec-2009, the patient experienced severe vomiting for one day. At the time of reporting patient had no symptom. The outcome for the reported adverse events was resolved on 04-Dec-2009.
On Tuesday morning client complained of head being bright red and arm was sore where the vaccine was administered.  Wednesday quarter sized whelps formed and itched.  Took Benadryl that night.  Thursday still haveing itching called MD on call with no return call.
(L) arm/hand "pinging" when I tap thumb & pinkie + ring finger together ; (L) forearm feels irritated & achy when resting it on any sfc, Face of shoulder felt achy warm to touch, tender at shot site, soft mass under surface. Back of (L) shoulder felt very sore, achy when touching a sfc (chairback, bed) Jaw  & whole body ached for 1st 24-36 hrs.  Tx: lymphatic massage on (L) arm/shoulder x 6. Hot/cold compresses 3x/evening x 4 more days. Homeopathic detoxing supplements. Spread out over last month. Recovery is slow.
This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to patient after the manufacture date of expiration) in a 78-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 prophylaxis. No Medical History information was reported. On 13-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 13-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to patient after the manufacture date of expiration). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to patient after the manufacture date of expiration) outcome was unknown. For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments. Concomitant medication was not reported. The vial did not undergo any temperature excursions. Total of 173 doses were given from LOT 070H21A. It was unknown when the vial was stored in refrigerator. Treatment medication was not reported. Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Live follow up received contains non -significant information.
had flu; Initial information was received on 08-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer via social media.  This case involves patient (unknown demography) who had flu (influenza), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment(s), concomitant medications, vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number, expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious had the flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE. It was reported that the patient got flu every time after the vaccination with influenza vaccine.  Details of laboratory data were not reported.   It was not reported if the patient received any corrective treatment.  Outcome of the event was unknown at the time of reporting.  There will be no information available on the batch number for this case.
Left upper arm pain, hardness at injection site.  Flu like symptoms, body aches, shivering without fever, malaise.
Information has been received from a nurse practitioner concerning a female who on 27-MAY-2009 was vaccinated with the first 0.5ml dose of GARDASIL (Lot# not provided). The patient did receive additional vaccines in the other arm on the same day she received GARDASIL, however there was no information regarding which vaccine the patient received. On 27-MAY-2009 after receiving GARDASIL the patient developed a raised, red, irritated rash at the injection site which was still present as of 10-AUG-2009. The patient had sought unknown medical attention. At the time of report the patient's status was not recovered. The second dose of GARDASIL was scheduled to be given on 10-AUG-2009, but was not given because of the rash. Follow-up information has been received indicated the correct address and the patient was 16 years old. Follow-up information has received from a nurse practitioner concerning the patient with a history of eczema, itchy skin and rashes and hives from ZITHROMAX and BACTRIM and with no illness at time of vaccination. The patient was vaccinated IM with the first dose of GARDASIL (Lot# 661953/1130X) in the right deltoid on 27-MAY-2009. On 27-MAY-2009 the patient also was vaccinated in her left arm with MENACTRA and hepatitis A virus vaccine inactivated (manufacturer unknown). The patient returned on 12-JUN-2009 with itchiness in both arms. The right arm was more severe than the left arm. On 12-AUG-2009 the patient returned stating she had persisted swelling at the injection site of GARDASIL. The patient had 3x2.5 cm red slightly raised firm area in the right deltoid. There were no relevant diagnostic tests performed. At the time of report the patients status was unknown. Additional information has been requested.
Redness and soreness at the injection site days two through five, Diarrhea, nausea, stomach pain, chills and fever (100.5) began at about 55 hours after injection, intense for four hours. Tiredness and body ache on days three and four.  The diarrhea, nausea, pain and fever were bad enough to make me report it...
Developed kindey infection following Moderna COVID 19 vaccine; Pain in legs; A spontaneous report was received from a pharmacist concerning a 51-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced  kidney infection(kidney infection)  following Moderna COVID 19 vaccine, and pain in legs/ pain in extremity.  The patient's medical history, was not provided by the reporter. No  concomitant product use was not provided by the reporter.  On 27 Feb 2021, approximately same day prior to the onset of the events, the patient received her first of two planned doses of mRNA-1273 (Lot number: 029A21A) intramuscularly for prophylaxis of COVID-19 infection.   On 27 Feb 2021, prior to receiving mRNA-1273, the patient developed kidney infection following Moderna COVID 19 vaccine with seriousness criteria as medically significant and  pain in legs.   Treatment for the events included antibiotic medication.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, developed kidney infection following Moderna COVID 19 vaccine, pain in legs were considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. On 04-FEB-2015 the patient was vaccinated with (Oka/Merck) VARIVAX (0.5 ml, subcutaneously) that underwent two temperature excursions. No adverse effects reported. This is one of several reports received from the same source. Additional information has been requested.
Sudden onset irritability, prolonged crying - cries of pain that were inconsolable, continuous for three hours until exhaustion, when stirred to nurse, woke up with same cries until exhaustion - 30 minutes later.
partial hearing loss, 20%; tinnitus; This is a spontaenous report from a contactable consumer. A 67-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 19Mar2021 (Lot Number: ER2613) as 1ST DOSE, SINGLE  for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced partial hearing loss, 20% and tinnitus on an unspecified date. The patient underwent lab tests and procedures which included Sars-Cov-2 antibody test: negative on 26Apr2021. Outcome of the events was unknown.   No follow-up attempts are needed. No further information is expected.
I was COVID-19 positive in March. It was a pretty severe flu, body ache, fever, diarrhea, sore throat, head ache, cough. It lasted severe for 7 days and started dwelling off for 8/9 days. Then I started feeling better.
fatigued; headaches; Voice still strained; Losing voice; Chills; Body ache; Fever; This spontaneous case was reported by a consumer and describes the occurrence of DYSPHONIA (Voice still strained), APHONIA (Losing voice), FATIGUE (fatigued), HEADACHE (headaches) and CHILLS (Chills) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 18-Jun-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jun-2021, the patient experienced CHILLS (Chills), MYALGIA (Body ache) and PYREXIA (Fever). On 20-Jun-2021, the patient experienced DYSPHONIA (Voice still strained) and APHONIA (Losing voice). On an unknown date, the patient experienced FATIGUE (fatigued) and HEADACHE (headaches). On 20-Jun-2021, CHILLS (Chills), MYALGIA (Body ache) and PYREXIA (Fever) had resolved. At the time of the report, DYSPHONIA (Voice still strained), FATIGUE (fatigued) and HEADACHE (headaches) had not resolved and APHONIA (Losing voice) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication were reported. No treatment information was reported
headaches; migraine; nausea; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 74 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 05Mar2021 (Lot number: EN6203) at the age of 74 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "diabetes" (unspecified if ongoing), notes: diagnosed about 5-10 years ago; "Congestive heart failure", start date: 2003 (unspecified if ongoing), notes: diagnosed in 2003 and hospitalized for a month. The patient's concomitant medications were not reported. The following information was reported: MIGRAINE (non-serious) with onset 05Mar2021, outcome "recovered" (07Mar2021), described as "migraine"; NAUSEA (non-serious) with onset 05Mar2021, outcome "recovered" (07Mar2021), described as "nausea"; HEADACHE (non-serious) with onset 11Mar2021, outcome "not recovered", described as "headaches".  Additional information: It was reported that patient had the first dose of the shot on 05Mar2021 and stated later on that day and the next day had a severe migraine with nausea and was resolved by 07Mar2021. Patient then stated that for two days she did not have anything, and then she started having intermittent headaches on 11Mar2021 and since then. She stated they were not as bad as the migraine but they come and go. Patient wanted to know if these headaches could still be related to the vaccination.  No follow-up attempts are possible. No further information is expected.
About the 35 minutes later became nausea and threw up, faint and blood pressure 190/106  she was sent to ER at time of admission blood pressure was going down and back to normal within hour and gave anti- nausea medicine . Blood pressure every :15 for hour 128/76 event resolve . Ondansetron  4 mg Face and  chest rash 24 hours later  Benadryl 25 mg
Headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Sep-2021, the patient experienced HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, HEADACHE (Headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.
pt recv vax;presented w/ a gradual onset of inflammation which resulted in an enlarged golf-ball like rxn at inject;
Information has been received from a physician , via a company representative, concerning a "teenaged" female patient, who on an unspecified date was vaccinated with the first dose of Gardasil (Lot # not provided). Concomitant therapy included MENACTRA. Subsequently, after receiving the first dose of Gardasil, the patient developed hives, that "were most severe on the injection site arm." The physician confirmed that the patient had recovered from the hives (duration and date not provided). The patient sought unspecified medical attention. The physician reported that three additional teenaged female patients also developed hives after vaccination with the first dose of Gardasil (lot # not provided (WAES: 0707USA00837, 0707USA01120, and 0707USA01122)). Additional information has been requested.
Within one hour of receiving the 11AM injection, my left shoulder became excruciating painful, with pain continuing down the arm.  Due to the pain I had little to no range of motion.  Neither aspirin nor NSAIDS had any effect on the pain.  By the following morning, most of the pain had gone, and it disappeared completely by mid-day.
Generalized maculopapular rash developed 5-4-13. The rash increased on 5-5-13. Has been the same since. On 4/26/13 had severe and was seen at a Clinic. Treated with Antibiotic (unknown none) for 8 days. Completed treatment by Fri 5/3/13. Rash started 5-4-13. Seen 5-5-13 at clinic. Started on Azythromycin for a Tonsillitis.
Information has been received from a 32 year old female patient with no known allergies or pertinent medical history who on 03-APR-2008 was vaccinated with a first dose of MMR II (Enders-Edmonston, Jeryl Lynn, Wister RA 27/3). There was no concomitant medication. it was noted that the patient had a "weird" feeling immediately after getting the vaccine." After 4-5 hours, her "tongue was fuzzy and swollen" and her throat started closing. The patient received epinephrine and BENADRYL intravenously to ease her symptoms. Subsequently, the patient recovered on an unspecified date. It was also noted that the patient had an itchy rash over her arms and upper body for 30 days after getting the vaccination. Thirty days after vaccination the patient had a titer drawn. The results were not reported. There was no product quality complaint involved. Upon internal review "tongue was fuzzy and swollen" and "throat started closing" were considered to be an other important medical events. Additional information has been requested.
Severe left deltoid pain, could not move arm for about a week. Did not seek treatment at time, was on school trip. To be evaluated by medical provider on 4/13/16.
Developed redness, swelling, and bruising the day of injection. On 07/15, developed pain from shoulder to wrist. Developed red streak of redness down arm. Seen at ER and given Cephalexin 500 mg for 3 days for infection at injection site. 07/21, improved with only bruising at injection site.
1/26, day after the shot [ within 24 hours} Wiped and noticed a blood clot 1/27 Bleeding Heavier, not like normal menstrual discharge. Have not had any significant discharge during menstruation due to being on the pill, however, bleeding come on within 24 hours of getting booster shot. Also bedridden with fever, nausea and vomiting at this stage, which lasted one day. Smell and consistency of blood NOT like normal menstrual blood.  1/28 Bleeding stopped